SMi Systems Welcomes Ronnie Andrews as New Non-Executive Director for Strategic Growth

SMi Systems Appoints Ronnie Andrews as Non-Executive Director

SMi Systems, a leading name in single-molecule detection technology aimed at drug discovery and diagnostics, has made a significant appointment to its Board of Directors. Ronnie Andrews, the Founder and Managing Partner of Bethesda Group Advisors, has been named Non-Executive Director as of November 10, 2025. This strategic addition comes at a crucial time for SMi Systems, aiming to further elevate its position in the life sciences sector.

For over three decades, Ronnie Andrews has been at the forefront of leadership in the Life Sciences Tools and Molecular Diagnostics sectors. His career boasts a remarkable breadth of experience ranging from Fortune 500 companies to innovative startups. Some of the notable organizations he has collaborated with include Abbott Diagnostics, Roche Molecular Diagnostics, GE, and Life Technologies/Thermo Fisher. He has also held prominent positions as CEO in public companies like Clarient Inc and Oncocyte Inc.

Andrews is also well-regarded as a trusted advisor for leading US venture capital firms, lending his expertise as Executive Chairman to emerging molecular technology companies. His impressive track record includes raising over $600 million in capital and facilitating more than $15 billion in strategic exits, showcasing both his financial acumen and leadership capabilities.

Dr. Andrew Thompson, CEO of SMi Systems, remarked on the significance of Andrews' appointment, stating, "Ronnie's proven expertise in scaling diagnostic and life science tools companies will be invaluable as we transition into our next growth phase. His insights and deep-rooted industry connections will strengthen our mission to enhance the accessibility and efficiency of molecular diagnostics and drug discovery on a global scale." This recruitment underscores SMi's commitment to assembling a leadership team that excels at innovation and commercial strategy.

Andrews expressed his excitement about joining SMi Systems at such a pivotal moment, stating, "I’m thrilled to be part of SMi Systems during this exciting period. The technology within the company possesses a uniquely broad potential to revolutionize patient outcomes and commercial success in the life sciences domain. I eagerly await the opportunity to support the teams in both the UK and the US as they prepare for market entry."

About SMi Systems

SMi Systems is an innovative life science technology company with a vision to enhance laboratory diagnostics through its automated single-molecule imaging platform. The company’s benchtop platform allows multiplexing and has assay flexibility that provides accurate and reliable detection for a range of molecule types in a single test. SMi Systems aims to deliver world-class results without the necessity of specialized knowledge or infrastructure.

By providing single-molecule data rapidly and at scale, SMi Systems supports informed decisions that drive the future of biomedical research and diagnostics. The company is committed to bringing its cutting-edge technology to every laboratory, facilitating improvements in healthcare and research.

For further information on SMi Systems and its innovative imaging technology, visit SMi Systems.